// App-Quantinova.ai

TCT-839 : Prognostic Significance of Established CAD in Patients with Left Main Disease Undergoing Revascularization: Analysis from EXCEL Trial

Researchers

Presenter

  • Matias Yudi

Principal Investigators

  • Roxana Mehran

  • Usman Baber

  • Aaron Crowley

  • Ori Ben-Yehuda

  • A. Pieter Kappetein

  • Joseph Sabik

  • Patrick Serruys

  • Gregg Stone

Medical Centers

  • Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York, United States

  • Imperial College, London, United Kingdom

  • Cardiovascular Research Foundation, Columbia University Medical Center, New York, New York, United States

  • Mount Sinai Health System, New York, New York, United States

  • Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands

  • Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, United States

  • Cardiovascular Research Foundation, Queens, New York, United States

Locations

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

Disease

  • Left main disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved